Recent Comments

Comment RSS

Osteonecrosis News and Research RSS Feed - Osteonecrosis News and Research

New market research report on techniques, technology and software used in life science data mining

27. October 2009 04:32
Reportlinker.com announces that a new market research report is available in its catalogue: Reportlinker Adds Data Mining in Drug Development and Translational Medicine [More]

Posted in: Pharmaceutical News

Tags: , , , , , , , ,

Reportlinker's medical review criteria guidelines for managing care

30. September 2009 08:03
Reportlinker Adds Medical Review Criteria Guidelines for Managing Care (8th ed. - 2009) [More]

Posted in: Healthcare News

Tags: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,

Amgen announces results of Phase 3 head-to-head trial evaluating denosumab versus Zometa

22. September 2009 07:28
Amgen (Nasdaq: AMGN) today announced detailed results from a Phase 3, head-to-head trial evaluating denosumab versus Zometa(R) (zoledronic acid) in the treatment of bone metastases in 2,046 patients with advanced breast cancer that met its primary and secondary endpoints and demonstrated superior efficacy compared to Zometa. [More]

Amgen announces results of Phase 3 trial in the treatment of bone metastases

21. September 2009 05:43
Amgen (Nasdaq: AMGN) today announced detailed results from a Phase 3 trial evaluating denosumab administered subcutaneously versus Zometa(R) (zoledronic acid) administered as an intravenous infusion in the treatment of bone metastases in 1,776 advanced cancer patients with solid tumors (not including breast and prostate cancer) or multiple myeloma. These results were presented today at the 2009 ECCO 15 - ESMO 34 European Multidisciplinary Congress in Berlin, Germany (Abstract Number: 20LBA). [More]

Amgen to present its four Phase 3 clinical trial results

16. September 2009 23:53
Amgen today announced it will present detailed data from four Phase 3 studies as well as other data at the ECCO 15 - ESMO 34 European Multidisciplinary Congress, September 20 - 24, 2009 in Berlin, Germany. [More]

Denosumab reduces fracture risk in men receiving androgen-deprivation therapy for prostate cancer

11. August 2009 19:04
Twice-yearly treatment with denosumab, a new targeted therapy to stop bone loss, increased bone density and prevented spinal fractures in men receiving androgen-deprivation therapy for prostate cancer. [More]

X-rays help predict permanent bone damage from bisphosphonates

7. May 2009 19:26
Breast cancer patients, individuals at risk for osteoporosis and those undergoing certain types of bone cancer therapies often take drugs containing bisphosphonates. These drugs have been found to place people at risk for developing osteonecrosis of the jaws (a rotting of the jaw bones). [More]

Childhood Varicella zoster could affect oral health years later

20. February 2009 11:45
You may recall as a child catching the itchy red rash, chicken pox. [More]

Oral bisphosphonates linked to increased jaw necrosis

1. January 2009 20:57
Researchers at the University Of Southern California, School Of Dentistry release results of clinical data that links oral bisphosphonates to increased jaw necrosis [More]

Posted in: Medical Research News

Tags: , , , , , ,

Zometa (zoledronic acid) shown to enhance chemotherapy in reducing breast tumor size

14. December 2008 21:02
New data released demonstrates that the addition of Zometa (zoledronic acid) injection to standard chemotherapy before breast cancer surgery reduces the size of breast tumors more effectively than chemotherapy alone in women with early-stage disease. [More]

FDA approves Actonel (risedronate sodium) for postmenopausal osteoporosis

24. April 2008 22:05
The U.S. Food and Drug Administration (FDA) approved a new once-a-month dose (150 mg) of Actonel (risedronate sodium) tablets for the treatment and prevention of postmenopausal osteoporosis. Actonel is approved to reduce the risk of fractures in postmenopausal women with osteoporosis. [More]

Cellular grafting procedure helps young patients with knee disorder get active

2. April 2008 04:05
At 14 years old, Adam Vasser of Los Altos, Calif., was an active kid who loved baseball. [More]

Bisphosphonates - osteoporosis drugs triple risk of bone necrosis

16. January 2008 05:38
A University of British Columbia and Vancouver Coastal Health Research Institute study has found that a popular class of osteoporosis drugs nearly triples the risk of developing bone necrosis, a condition that can lead to disfigurement and incapacitating pain. [More]

New method predicts hip joint decay from chemotherapy

27. May 2007 19:31
St. Jude investigators say they have found the best way for predicting when patients will need future surgery to repair hip joints that have deteriorated because of pediatric leukemia or lymphoma treatment. [More]

Posted in: Drug Trial News

Tags: , , , , , , ,

New method predicts hip joint decay from chemotherapy

20. April 2007 11:55
Investigators at St. Jude Children's Research Hospital say they have found the best way for predicting when patients will need future surgery to repair hip joints that have deteriorated because of pediatric leukemia or lymphoma treatment. [More]

Posted in: Medical Research News

Tags: , , , , , , ,

News-Medical.Net provides this medical information service in accordance with these terms and conditions. Please note that medical information found on this website is designed to support, not to replace the relationship between patient and physician/doctor and the medical advice they may provide.